Goldman Sachs’s Viking Therapeutics VKTX Stock Holding History

Goldman Sachs’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-145,500	Closed	-$5.12M	–	7016
2025 Q4	$5.12M	Buy	145,500 +85,500	+143%	+$3.03M	﹤0.01%	3726
2025 Q3	$1.58M	Sell	60,000 -30,000	-33%	-$895K	﹤0.01%	4683
2025 Q2	$2.38M	Buy	90,000 +45,000	+100%	+$1.18M	﹤0.01%	4042
2025 Q1	$1.09M	Buy	45,000 +35,000	+350%	+$1.11M	﹤0.01%	4622
2024 Q4	$402K	Buy	+10,000	New	+$570K	﹤0.01%	5358
2024 Q3	–	Sell	-128,300	Closed	-$6.8M	–	6088
2024 Q2	$6.8M	Buy	+128,300	New	+$8.41M	﹤0.01%	2874
2023 Q2	–	Sell	-196,200	Closed	-$3.27M	–	6088
2023 Q1	$3.27M	Buy	+196,200	New	+$2.03M	﹤0.01%	3449

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs's VKTX Position: Q1 2026 in Review

Goldman Sachs increased its Viking Therapeutics (VKTX) stake by 15% in Q1 2026, buying an estimated $4.11M and bringing the position to 960,570 shares worth $31.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2016.

Goldman Sachs first reported a position in VKTX in Q2 2015 and has held it in 37 quarters since. The position peaked at $56.9M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Goldman Sachs held 960,570 shares of Viking Therapeutics worth $31.3M as of Q1 2026.
Goldman Sachs bought 127,919 Viking Therapeutics shares in Q1 2026, an estimated $4.11M.
Viking Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2016 holding.
Goldman Sachs first reported a position in Viking Therapeutics in Q2 2015 and has held it in 37 quarters since.
Goldman Sachs's Viking Therapeutics position peaked at $56.9M in Q2 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.